Guest
Nimotuzumab is a humanized monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR). Nimotuzumab inhibits activation of the protein tyrosine kinase and has a slightly lower binding affinity compared to other common EGFR-targeting agents. Nimotuzumab is being evaluated in clinical studies around the world in multiple indications including non-small cell lung cancer, pediatric and adult glioma, esophageal cancer, pancreatic cancer, gastric cancer and head & neck cancer. Nim
